Company / Goodwill
Neurocrine Biosciences Goodwill History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Goodwill
$5.7M
FY2024
5-year range
$0 / $5.8M
FY2021-FY2024
Trend
-1.7%
vs FY2023
Sector context
#64 of 76
Health Care
What the data says
Neurocrine Biosciences's goodwill of $6M is lower than 84% of companies in the Health Care sector (FY2024). Improved from $5M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2024.
Improved from $5M to $6M over the past 2 years.
Health Care sector context is included.
Goodwill over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 76This company $5.7M Sector average $3.9B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, goodwill decreased 1.7% year-over-year.
- Ranks #64 out of 76 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | GoodwillValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $5.7M | -1.7% |
| FY2023 | $5.8M | +7.4% |
| FY2022 | $5.4M | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026